CN109476653B - 类视黄醇相关孤儿受体γ的杂芳族调节剂 - Google Patents

类视黄醇相关孤儿受体γ的杂芳族调节剂 Download PDF

Info

Publication number
CN109476653B
CN109476653B CN201780043425.2A CN201780043425A CN109476653B CN 109476653 B CN109476653 B CN 109476653B CN 201780043425 A CN201780043425 A CN 201780043425A CN 109476653 B CN109476653 B CN 109476653B
Authority
CN
China
Prior art keywords
methyl
phenyl
oxadiazol
amino
piperazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201780043425.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN109476653A (zh
Inventor
A·S·杰西曼
P·S·约翰逊
K·马安森
M·D·瑟伦森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leo Pharma AS
Original Assignee
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma AS filed Critical Leo Pharma AS
Publication of CN109476653A publication Critical patent/CN109476653A/zh
Application granted granted Critical
Publication of CN109476653B publication Critical patent/CN109476653B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
CN201780043425.2A 2016-07-13 2017-07-11 类视黄醇相关孤儿受体γ的杂芳族调节剂 Expired - Fee Related CN109476653B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020268.5 2016-07-13
EP16020268 2016-07-13
PCT/EP2017/067390 WO2018011201A1 (en) 2016-07-13 2017-07-11 Heteroaromatic modulators of the retinoid-related orphan receptor gamma

Publications (2)

Publication Number Publication Date
CN109476653A CN109476653A (zh) 2019-03-15
CN109476653B true CN109476653B (zh) 2022-04-22

Family

ID=56511303

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780043425.2A Expired - Fee Related CN109476653B (zh) 2016-07-13 2017-07-11 类视黄醇相关孤儿受体γ的杂芳族调节剂

Country Status (21)

Country Link
US (2) US10662181B2 (https=)
EP (1) EP3484880B1 (https=)
JP (1) JP7016344B2 (https=)
KR (1) KR102490140B1 (https=)
CN (1) CN109476653B (https=)
AU (1) AU2017294969B2 (https=)
BR (1) BR112019000486A2 (https=)
CA (1) CA3030370A1 (https=)
DK (1) DK3484880T3 (https=)
ES (1) ES2834009T3 (https=)
IL (1) IL264141B (https=)
MX (1) MX383770B (https=)
MY (1) MY196990A (https=)
PL (1) PL3484880T3 (https=)
PT (1) PT3484880T (https=)
RU (1) RU2771280C2 (https=)
SA (1) SA519400868B1 (https=)
SG (1) SG11201811107WA (https=)
UA (1) UA123330C2 (https=)
WO (1) WO2018011201A1 (https=)
ZA (1) ZA201808436B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109476653B (zh) * 2016-07-13 2022-04-22 利奥制药有限公司 类视黄醇相关孤儿受体γ的杂芳族调节剂
CN111825654A (zh) * 2019-04-19 2020-10-27 北京酷瓴生物技术有限公司 苯甲烯哌啶衍生物及其制备方法、中间体和用途
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299121A1 (en) * 2012-12-06 2015-10-22 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS244821B2 (en) * 1983-06-16 1986-08-14 Boehringer Ingelheim Ltd Production method of new substituted phenylalkyl(piperazinyl or homopiperazinyle)-prpylureas or thioureas
WO2004073612A2 (en) 2003-02-13 2004-09-02 Merck & Co. Inc. Estrogen receptor modulators
FR2879381B1 (fr) 2004-12-15 2008-12-26 Thales Sa Systeme de distribution quantique de cle de cryptage a variables continues
AU2006231929B2 (en) * 2005-04-04 2012-09-06 Ab Science Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
EP2511275A1 (en) 2011-04-12 2012-10-17 Bioprojet Novel piperidinyl monocarboxylic acids as S1P1 receptor agonists
CN105705492B (zh) * 2013-11-05 2019-11-05 豪夫迈·罗氏有限公司 作为rorc调节剂用于治疗自身免疫性疾病的5,6,7,8-四氢-5,8-亚甲基噌啉衍生物
WO2015180613A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
CN109476653B (zh) * 2016-07-13 2022-04-22 利奥制药有限公司 类视黄醇相关孤儿受体γ的杂芳族调节剂

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150299121A1 (en) * 2012-12-06 2015-10-22 Glaxo Group Limited Modulators of the retinoid-related orphan receptor gamma (ror-gamma) for use in the treatment of autoimmune and inflammatory diseases
CN105121430A (zh) * 2012-12-06 2015-12-02 葛兰素集团有限公司 用于治疗自身免疫性和炎性疾病的类维生素A相关的孤儿受体γ(RORγ)的调节剂
WO2015180612A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds
WO2015180614A1 (en) * 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Novel compounds

Also Published As

Publication number Publication date
KR20190026872A (ko) 2019-03-13
MX2019000361A (es) 2019-05-23
RU2019103883A3 (https=) 2020-09-23
AU2017294969B2 (en) 2021-03-25
KR102490140B1 (ko) 2023-01-19
US20200291010A1 (en) 2020-09-17
JP2019521137A (ja) 2019-07-25
EP3484880A1 (en) 2019-05-22
RU2019103883A (ru) 2020-08-13
EP3484880B1 (en) 2020-09-02
US10934282B2 (en) 2021-03-02
BR112019000486A2 (pt) 2019-04-24
PT3484880T (pt) 2020-12-07
US10662181B2 (en) 2020-05-26
AU2017294969A1 (en) 2019-01-17
ZA201808436B (en) 2020-05-27
DK3484880T3 (da) 2020-11-09
ES2834009T3 (es) 2021-06-16
IL264141A (en) 2019-02-28
WO2018011201A1 (en) 2018-01-18
US20190284177A1 (en) 2019-09-19
CN109476653A (zh) 2019-03-15
UA123330C2 (uk) 2021-03-17
CA3030370A1 (en) 2018-01-18
SA519400868B1 (ar) 2022-06-13
SG11201811107WA (en) 2019-01-30
JP7016344B2 (ja) 2022-02-04
MY196990A (en) 2023-05-17
MX383770B (es) 2025-03-14
RU2771280C2 (ru) 2022-04-29
NZ749301A (en) 2021-03-26
PL3484880T3 (pl) 2021-04-06
IL264141B (en) 2021-09-30

Similar Documents

Publication Publication Date Title
AU2020267169B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
JP7365059B2 (ja) 縮合チオフェン化合物
RU2610840C2 (ru) Тиазолопиримидины
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
KR20230007352A (ko) Kdm5 억제 활성을 갖는 화합물 및 이의 약학적 용도
CN109476653B (zh) 类视黄醇相关孤儿受体γ的杂芳族调节剂
CA3129851A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
AU2018237987B2 (en) Isoxazole carboxamide compounds and uses thereof
CN113677659B (zh) 可用作类法尼醇x受体调节剂的经取代的酰胺化合物
KR20180050408A (ko) 국부 약물 전달용의 비스테로이드성 글루코코르티코이드 수용체 조절제
HK40005345A (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
CA3129619A1 (en) Substituted amide compounds useful as farnesoid x receptor modulators
KR20230065914A (ko) Kdm5 억제 활성을 갖는 화합물을 포함하는 약학 조성물
NZ749301B2 (en) Heteroaromatic modulators of the retinoid-related orphan receptor gamma
HK1258975B (zh) 用於局部药物递送的非甾体类糖皮质激素受体调节剂
HK40039990B (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
NZ786241A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
HK1261874A1 (en) New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40005345

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20220422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40005345

Country of ref document: HK